Home › Kanser sa Bato (Renal Cell Carcinoma) › Ohio

Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Ohio

26 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Ohio.

Mga Lungsod sa Ohio

Opisyal na teksto ng pag-aaral (English)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site, Cleveland
Research Site, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NEO-811 Cleveland Site, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07300241

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

University Hospitals Cleveland Medical Center, Cleveland
Cleveland Clinic, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Summa Health System - Akron Campus, Akron
Cleveland Clinic Akron General, Akron
Summa Health System - Barberton Campus, Barberton
at 44 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #10, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Strecker Cancer Center-Belpre, Belpre
Adena Regional Medical Center, Chillicothe
Ohio State University Comprehensive Cancer Center, Columbus
at 22 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Ohio State University Comprehensive Cancer Center, Columbus

Nagre-recruitPhase 2

Edad 12 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04981509

DESTINY-PANTUMOUR04

Research Site, Canton
Research Site, Maumee

Nagre-recruitObservasyonal na pag-aaral

Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

The Ohio State University Comprehensive Cancer Center, Columbus

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04981119

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Local Institution - 0135, Cincinnati
Cleveland Clinic, Cleveland

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07293351

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Ohio State University Comprehensive Cancer Center, Columbus

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06863311

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Miami Valley Hospital South, Centerville
at 13 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05327686

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Aultman Health Foundation, Canton
at 10 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

University Hospitals Seidman Cancer Center, Cleveland
Cleveland Clinic, Cleveland

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05361720

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Cleveland Clinic, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06966024

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Xencor Investigative Site, Cincinnati
Xencor Investigative Site, Columbus

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05433142

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

James Cancer Hospital and Solove Research Institute, Columbus

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT03972657

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Ohio State University, Columbus

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT06026410

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Cleveland Clinic, Cleveland

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update May 8, 2026 · NCT05363280

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

The Ohio State University Wexner Medical Center, Columbus

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Lahat ng edad · Lahat ng kasarian · Na-update Mar 9, 2026 · NCT04792463

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Gabrail Cancer & Research Center, Canton

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Dis 17, 2025 · NCT05856981

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Case Comprehensive Cancer Center, Cleveland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2025 · NCT06805825

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The Ohio State University, Columbus

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT06682793

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

UH Seidman Cancer Center at UH Avon Health Center, Avon
UHHS-Chagrin Highlands Medical Center, Beachwood
Indu and Raj Soin Medical Center, Beavercreek
at 20 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04510597

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Cleveland Clinic, Cleveland

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 25, 2024 · NCT05824975

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.